array:24 [
  "pii" => "S1578219020300147"
  "issn" => "15782190"
  "doi" => "10.1016/j.adengl.2019.11.005"
  "estado" => "S300"
  "fechaPublicacion" => "2020-03-01"
  "aid" => "2275"
  "copyright" => "AEDV"
  "copyrightAnyo" => "2019"
  "documento" => "simple-article"
  "crossmark" => 1
  "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
  "subdocumento" => "cor"
  "cita" => "Actas Dermosifiliogr. 2020;111:87"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "es" => array:20 [
      "pii" => "S0001731019303771"
      "issn" => "00017310"
      "doi" => "10.1016/j.ad.2019.11.001"
      "estado" => "S300"
      "fechaPublicacion" => "2020-03-01"
      "aid" => "2275"
      "copyright" => "AEDV"
      "documento" => "simple-article"
      "crossmark" => 1
      "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
      "subdocumento" => "cor"
      "cita" => "Actas Dermosifiliogr. 2020;111:87"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 37
        "formatos" => array:2 [
          "HTML" => 19
          "PDF" => 18
        ]
      ]
      "es" => array:10 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Comentario editorial</span>"
        "titulo" => "Apremilast en psoriasis"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "paginas" => array:1 [
          0 => array:1 [
            "paginaInicial" => "87"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Apremilast in Psoriasis"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "A&#46; P&#233;rez Ferriols"
            "autores" => array:1 [
              0 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "P&#233;rez Ferriols"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S1578219020300147"
          "doi" => "10.1016/j.adengl.2019.11.005"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219020300147?idApp=UINPBA000044"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731019303771?idApp=UINPBA000044"
      "url" => "/00017310/0000011100000002/v2_202009190635/S0001731019303771/v2_202009190635/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:20 [
    "pii" => "S1578219020300135"
    "issn" => "15782190"
    "doi" => "10.1016/j.adengl.2019.03.029"
    "estado" => "S300"
    "fechaPublicacion" => "2020-03-01"
    "aid" => "2193"
    "copyright" => "AEDV"
    "documento" => "simple-article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "cor"
    "cita" => "Actas Dermosifiliogr. 2020;111:87-8"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Commentaries</span>"
      "titulo" => "Early Syphilis&#58; New Diagnostic Approaches in a Changing Scenario"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "87"
          "paginaFinal" => "88"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "S&#237;filis precoz&#58; nuevas aproximaciones diagn&#243;sticas para un escenario cambiante"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "T&#46; Toledo Pastrana"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "T&#46;"
              "apellidos" => "Toledo Pastrana"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0001731019301279"
        "doi" => "10.1016/j.ad.2019.03.002"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731019301279?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219020300135?idApp=UINPBA000044"
    "url" => "/15782190/0000011100000002/v1_202004140647/S1578219020300135/v1_202004140647/en/main.assets"
  ]
  "en" => array:12 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Commentaries</span>"
    "titulo" => "Apremilast in Psoriasis"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:1 [
        "paginaInicial" => "87"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "A&#46; P&#233;rez Ferriols"
        "autores" => array:1 [
          0 => array:3 [
            "nombre" => "A&#46;"
            "apellidos" => "P&#233;rez Ferriols"
            "email" => array:1 [
              0 => "perez_ampferr@gva.es"
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital General Universitario&#44; Valencia&#44; Spain"
            "identificador" => "aff0005"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Apremilast en psoriasis"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">The authors present the results of a Delphi study conducted in Spain on the use of apremilast in psoriasis&#46;<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> Apremilast is a &#8220;small-molecule&#8221; oral phosphodiesterase 4 inhibitor that according to its summary of product characteristics is indicated for the treatment of psoriatic arthritis and chronic moderate to severe plaque psoriasis&#46; The position of apremilast in the current arsenal of treatments for psoriasis has been influenced by several factors&#46; First&#44; its limited effectiveness compared with other alternatives&#59; second its adverse effects&#44; which in many cases require withdrawal of treatment due to poor tolerability&#59; and last but not least&#44; its cost&#44; which is similar to that of the most effective biologic drugs available and higher than that of other biosimilars&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">The authors&#44; all experts in psoriasis&#44; chose 5 points of interest to analyze using a Delphi questionnaire&#46; After reviewing each point based on the existing literature&#44; the panel concluded that apremilast might be a treatment option for patients with a different profile to that studied in the clinical trials&#46; They highlight the need for a consensus-based definition of moderate psoriasis&#44; which is where apremilast could possibly be positioned as a treatment option preceding biologic therapy&#46; Finally&#44; they stress the need for more scientific evidence from clinical trials and real-world studies to verify the opinions expressed in this study&#46;</p></span>"
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as&#58; P&#233;rez Ferriols A&#46; Apremilast en psoriasis&#46; Actas Dermosifiliogr&#46; 2020&#59;111&#58;87&#46;</p>"
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Reference"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:1 [
            0 => array:3 [
              "identificador" => "bib0005"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Estudio Delphi para el uso de apremilast en psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "J&#46;M&#46; Carrascosa"
                            1 => "I&#46; Belinch&#243;n"
                            2 => "R&#46; Rivera"
                            3 => "M&#46; Ara"
                            4 => "M&#46; Bustinduy"
                            5 => "P&#46; Herranz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Actas Dermosifilogr"
                        "fecha" => "2020"
                        "volumen" => "111"
                        "paginaInicial" => "115"
                        "paginaFinal" => "134"
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/15782190/0000011100000002/v1_202004140647/S1578219020300147/v1_202004140647/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "66476"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Commentaries"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/15782190/0000011100000002/v1_202004140647/S1578219020300147/v1_202004140647/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219020300147?idApp=UINPBA000044"
]
Share
Journal Information
Vol. 111. Issue 2.
Pages 87 (March 2020)
Commentaries
Open Access
Apremilast in Psoriasis
Apremilast en psoriasis
Visits
3501
A. Pérez Ferriols
Servicio de Dermatología, Hospital General Universitario, Valencia, Spain
This item has received

Under a Creative Commons license
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text

The authors present the results of a Delphi study conducted in Spain on the use of apremilast in psoriasis.1 Apremilast is a “small-molecule” oral phosphodiesterase 4 inhibitor that according to its summary of product characteristics is indicated for the treatment of psoriatic arthritis and chronic moderate to severe plaque psoriasis. The position of apremilast in the current arsenal of treatments for psoriasis has been influenced by several factors. First, its limited effectiveness compared with other alternatives; second its adverse effects, which in many cases require withdrawal of treatment due to poor tolerability; and last but not least, its cost, which is similar to that of the most effective biologic drugs available and higher than that of other biosimilars.

The authors, all experts in psoriasis, chose 5 points of interest to analyze using a Delphi questionnaire. After reviewing each point based on the existing literature, the panel concluded that apremilast might be a treatment option for patients with a different profile to that studied in the clinical trials. They highlight the need for a consensus-based definition of moderate psoriasis, which is where apremilast could possibly be positioned as a treatment option preceding biologic therapy. Finally, they stress the need for more scientific evidence from clinical trials and real-world studies to verify the opinions expressed in this study.

Reference
[1]
J.M. Carrascosa, I. Belinchón, R. Rivera, M. Ara, M. Bustinduy, P. Herranz.
Estudio Delphi para el uso de apremilast en psoriasis.
Actas Dermosifilogr, 111 (2020), pp. 115-134

Please cite this article as: Pérez Ferriols A. Apremilast en psoriasis. Actas Dermosifiliogr. 2020;111:87.

Copyright © 2019. AEDV
Download PDF
Idiomas
Actas Dermo-Sifiliográficas
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?